The University of Chicago Header Logo

Connection

Mark Lingen to Administration, Oral

Back to Details
This is a "connection" page, showing publications Mark Lingen has written about Administration, Oral.
Mark Lingen
Connection Strength
0.027
Administration, Oral
  1. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol. 2016 Feb; 2(2):209-16.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.